Showing 1671-1680 of 9336 results for "".
- Positive Results for Dermavant's Vtama in Pediatric Maximal Usage Study in Atopic Dermatitishttps://practicaldermatology.com/news/positive-results-for-dermavants-vtama-in-pediatric-maximal-usage-study-in-atopic-dermatitis/2461418/Dermavant Sciences shared positive results from its maximal usage study of Vtama (tapinarof) cream 1% in children down to age 2 years old with extensive burden of atopic dermatitis. “We are delighted with the results from our maximal usage study of Vtama cream 1% in atopic dermatitis, which for th…
- Monkeypox Update: Kids Aged 8 or Younger at High Risk for More Severe Monkeypoxhttps://practicaldermatology.com/news/monkey-pox-update-kids-aged-8-or-younger-at-high-risk-for-more-severe-monkeypox/2461409/Children aged 8 years or younger are at high risk for more severe monkeypox disease, reports The Pediatric Infectious Disease Journal. Young children would be a key target group for smallpox vaccination and other urgent measures if the outbreak widens, according to the review by Petra Zimmermann, …
- Almirall’s New Psoriasis Campaign Sheds Light on How the Disease Affects Mental Health and Wellbeinghttps://practicaldermatology.com/news/almiralls-new-psoriasis-campaign-sheds-light-on-how-the-disease-affects-mental-health-and-wellbeing/2461407/Almirall and the International Federation of Psoriasis Association are launching the second edition of the "Shedding Light on Psoriasis" campaign for World Psoriasis Day 2022. Shedding Light on Psoriasis aims to elevate the stories of people living with psoriasis and show how the dark side of psor…
- EWG: FDA Must Ban Oxybenzone in Sunscreen Now!https://practicaldermatology.com/news/ewg-fda-must-ban-oxybenzone-in-sunscreen-now/2461405/The U.S. Food and Drug Administration (FDA) should ban oxybenzone in sunscreens, according to researchers at the Environmental Working Group (EWG). For decades, sunscreen makers have used oxybenzone in their products, despite concerns about its health harms. In 2021, the FDA told these companies: …
- New Aveeno Report Reveals 71% of Adults Have Sensitive Skinhttps://practicaldermatology.com/news/new-aveeno-report-reveals-71-of-adults-have-sensitive-skin/2461401/The Aveeno brand has launched its first-ever State of Skin Sensitivity Report, which examines the causes of sensitive skin, and explores the connection between body, mind, and skin. While body positivity has spread to mainstream culture in recent years, self-love can be challenging for those of us …
- Nivolumab Shows Promise in Advanced SCChttps://practicaldermatology.com/news/nivolumab-shows-promise-in-advanced-scc/2461399/Numerous studies have shown that immune checkpoint inhibitors can boost the immune system’s response against various cancers, and now, a phase II clinical trial has demonstrated that patients with advanced cutaneous squamous cell carcinoma can benefit from nivolumab. The research is published onlin…
- Hair Straightening Chemicals Associated with Higher Uterine Cancer Riskhttps://practicaldermatology.com/news/hair-straightening-chemicals-associated-with-higher-uterine-cancer-risk/2461397/Chemical hair straighteners may be contributing to a rise in aggressive uterine cancers a new study in the Journal of the National Cancer Institute suggests. There were no associations with uterine cancer for other hair products that the women reported using, including hair dyes, bleach, highligh…
- Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosishttps://practicaldermatology.com/news/seborrheic-dermatitis-survey-shows-burdensome-and-lengthy-path-to-diagnosis/2461396/Arcutis Biotherapeutics, Inc., shared results of a nationwide survey of adults with seborrheic dermatitis and the health care providers who treat them that highlights the long path to diagnosis and the general lack of awareness and education about the disease. The online survey was conducted by The…
- Phase 3 Data: Opdivo Reduced Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Melanomahttps://practicaldermatology.com/news/phase-3-data-opdivo-reduced-risk-of-recurrence-or-death-by-58-versus-placebo-in-patients-with-completely-resected-stage-iib-or-iic-melanoma/2461391/Bristol Myers Squibb shared results from the Phase 3 CheckMate -76K trial, in which Opdivo (nivolumab) as an adjuvant therapy demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival (RFS) versus placebo in patients with completely resected stage IIB or…
- #NationalMenopauseDay Launch: VICHY Laboratoires Introduces Neovadiol Meno 5 Serumhttps://practicaldermatology.com/news/national-menopause-day-launch-vichy-laboratoires-introduces-neovadiol-meno-5-serum/2461388/VICHY Laboratoires is launching of Neovadiol Meno 5 Serum, a product line developed for peri- and post-menopausal skin. The serum launches on #WorldMenopauseDay. The lightweight oil-in-water serum will nourish and firm the skin while improving the look of dark spots and wrinkles and boosting ra…